Cite
HARVARD Citation
Hafner, M. et al. (2019). Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell chemical biology. 26 (8), pp. 1067-1080.e8. [Online].